alrestatin inhibitor aldose reductase enzyme involved pathogenesis complications diabetes mellitus including diabetic alrestat first synthesized first aldose reductase inhibitor ari oral bioavailability undergo clinical trials late early lowquality trials high incidence adverse effects particularly hepatotoxicity led termination development never clinical structurally related tolrestat another ari briefly marketed withdrawn alrestatin synthesized reaction naphthalic anhydride httpsenwikipediaorgwikialrestatin